Quidelortho Corporation · NASDAQ:QDEL
Quidelortho — Q2 2025 Earnings Presentation
18 slides from Quidelortho's earnings presentation, Aug 5, 2025
Slide 1: QuidelOrtho Second Quarter 2025 Financial Results
August 5, 2025 QuidelOrtho Second Quarter 2025 Financial Results
Slide 2: Forward-Looking Statements and Non-GAAP Financial Measures
QuidelOrtho – Proprietary & Confidential. |© 2025. All Rights Reserved. 2 Forward-Looking Statements and Non-GAAP Financial Measures Forward-Looking Statements: This presentation of QuidelOrtho Corporation (“QuidelOrtho” or the “Company”) contains “forward-looking statements” within the meaning of t
Slide 3: Q2 2025 Highlights
QuidelOrtho – Proprietary & Confidential. |© 2025. All Rights Reserved. 3 Q2 2025 Highlights1 Total Revenue $614M Business Unit Geography Category (4%) y/y1 Adjusted Labs North America EBITDA 57% 51% EMEA 12% $107M 4 2 China Recurring Point 12% 82% of Care Other 26% 19% 17% Margin2 Adjusted Diluted
Slide 4: YTD 2025 Highlights
QuidelOrtho – Proprietary & Confidential. |© 2025. All Rights Reserved. 4 YTD 2025 Highlights1 Total Revenue $1.31B Business Unit Geography Category (2%) y/y1 Adjusted North America EBITDA Labs 51% 58% EMEA 12% $267M 2 China Recurring Point 84% 12% of Care Other 25% 20% Margin2 18% Adjusted Diluted
Slide 5: Q2 2025 Operating Results Summary
QuidelOrtho – Proprietary & Confidential. |© 2025. All Rights Reserved. 5 Q2 2025 Operating Results Summary1 Fiscal Quarter Year to Date Q2 2025 Q2 2024 Q2 2025 Q2 2024 Total Revenue $613.9 $637.0 $1,306.7 $1,348.0 Constant Currency2 Growth (3.9%) (2.4%) Recurring Revenue3 $592.0 $604.9 $1,257.4 $1,
Slide 6: Q2 2025 Cash Flow and Balance Sheet
QuidelOrtho – Proprietary & Confidential. |© 2025. All Rights Reserved. 6 Q2 2025 Cash Flow and Balance Sheet Balance Sheet Q2 2025 Cash Flow1 (as of June 29, 2025) $(32)M $15M $152M ~4.2x Q2 Adjusted YTD Adjusted Net Debt to Cash Free Cash Flow2 Free Cash Flow3 Adjusted EBITDA4 $24M $77M $2.6B ~3.3
Slide 7: FY 2025 Financial Guidance
QuidelOrtho – Proprietary & Confidential. |© 2025. All Rights Reserved. 7 FY 2025 Financial Guidance1 Assumptions Revenue • Labs business growth expected in the mid-single digits Financial Outlook FY 2025 • Transfusion Medicine business growth, excluding Donor Screening, expected in the low- single
Slide 8: Appendix
Appendix @® QuidelOrtho
Slide 9: Non-GAAP Adjustments
QuidelOrtho – Proprietary & Confidential. |© 2025. All Rights Reserved. 9 Non-GAAP Adjustments Fiscal Quarter Year to Date In millions Q2 2025 Q2 2024 Q2 2025 Q2 2024 Incremental depreciation on PP&E fair value adjustment $ 3.3 $ 5.4 $ 6.6 $ 10.9 Amortization of deferred cloud computing implementati
Slide 10: QTD Non-GAAP Reconciliation
QuidelOrtho – Proprietary & Confidential. |© 2025. All Rights Reserved. 10 QTD Non-GAAP Reconciliation Fiscal Quarter Q2 2025 Fiscal Quarter Q2 2024 In millions GAAP Adjustments (a) Non-GAAP GAAP Adjustments (a) Non-GAAP Gross profit $ 274.9 $ 5.6 $ 280.5 $ 276.0 $ 5.5 $ 281.5 Selling, marketing and
Slide 11: YTD Non-GAAP Reconciliation
QuidelOrtho – Proprietary & Confidential. |© 2025. All Rights Reserved. 11 YTD Non-GAAP Reconciliation Year to Date Q2 2025 Year to Date Q2 2024 In millions GAAP Adjustments (a) Non-GAAP GAAP Adjustments (a) Non-GAAP Gross profit $ 618.2 $ 9.2 $ 627.4 $ 608.1 $ 11.3 $ 619.4 Selling, marketing and ad
Slide 12: Revenue by Geography
QuidelOrtho – Proprietary & Confidential. |© 2025. All Rights Reserved. 12 Revenue by Geography Three Months Ended 2024 2025 Second Quarter Constant Less: COVID- Currency Q1 Q2 Q3 Q4 Q1 Q2 Percent Currency Constant (a) 19 Revenue ex COVID-19 Change Impact Currency (a) Impact Revenue North America $4
Slide 13: Revenue by Business Unit
QuidelOrtho – Proprietary & Confidential. |© 2025. All Rights Reserved. 13 Revenue by Business Unit Three Months Ended 2024 2025 Second Quarter Constant Less: COVID- Currency Q1 Q2 Q3 Q4 Q1 Q2 Percent Currency Constant (a) 19 revenue ex COVID-19 Change Impact Currency (a) impact Revenue Labs $357.1
Slide 14: Revenue by Respiratory and Non-Respiratory
QuidelOrtho – Proprietary & Confidential. |© 2025. All Rights Reserved. 14 Revenue by Respiratory and Non-Respiratory Three Months Ended 2024 2025 Second Quarter Constant Less: COVID- Currency Q1 Q2 Q3 Q4 Q1 Q2 Percent Currency Constant (a) 19 revenue ex COVID-19 Change Impact Currency (a) impact Re
Slide 15: Non-GAAP Reconciliations
QuidelOrtho – Proprietary & Confidential. |© 2025. All Rights Reserved. 15 Non-GAAP Reconciliations Three Months Ended June 29, 2025 June 30, 2024 Percent Change Currency Impact Constant Currency (a) Total revenues $613.9 $637.0 (3.6)% 0.3% (3.9)% COVID-19 revenue (9.5) (18.9) (49.7)% 1.2% (50.9)% D
Slide 16: Non-GAAP Reconciliations
QuidelOrtho – Proprietary & Confidential. |© 2025. All Rights Reserved. 16 Non-GAAP Reconciliations Three Months Ended June 29, 2025 June 30, 2024 Percent Change Currency Impact Constant Currency (a) Latin America 60.2 57.0 5.6% (8.8)% 14.4% Japan and Asia-Pacific 72.3 67.2 7.6% 1.6% 6.0% Other regi
Slide 17: Non-GAAP Reconciliations – Adjusted EBITDA
QuidelOrtho – Proprietary & Confidential. |© 2025. All Rights Reserved. 17 Non-GAAP Reconciliations – Adjusted EBITDA Fiscal Quarter Year to Date In millions Q2 2025 Q2 2024 Q2 2025 Q2 2024 Net loss $ (255.4) $ (147.7) $ (268.1) $ (1,853.7) Depreciation and amortization 110.3 116.1 217.4 231.0 Inter
Slide 18: quidelortho.com
quidelortho.com